Department of Hypertension and Cardiorenal Medicine, Dokkyo Medical University, Mibu, Tochigi, Japan.
Hypertens Res. 2010 Sep;33(9):965-73. doi: 10.1038/hr.2010.112. Epub 2010 Jul 22.
We and others recently reported that long-term Rho-kinase inhibition has renoprotective effects. This study was designed to compare the effects of an angiotensin-converting enzyme (ACE) inhibitor (imidapril), a Rho-kinase inhibitor (fasudil) and a combination of them both on renal interstitial fibrosis induced by unilateral ureteral obstruction (UUO). We also attempted to elucidate the mechanism involved. Imidapril (50 mg l(-1)), fasudil (1 g l(-1)) or a combination of them both was given in drinking water to mice, and their effects were compared on renal interstitial fibrosis induced by UUO. We assessed histological findings, monocyte/macrophage infiltration, myofibroblast differentiation, oxidative stress and the expression of various mRNA in the kidney by UUO. Eleven days after UUO, wild-type kidney was characterized by increased fibrotic area, dihydroethidium (DHE)-positive area, alpha-smooth muscle actin (SMA)-positive area, F4/80-positive area and the increased expression of various mRNA. Fasudil and imidapril similarly improved fibrotic area (-23%, -15%), DHE-positive area (-13%, -11%), alpha-SMA-positive area (-22%, -15%), F4/80-positive area (-42%, -34%) and the expression of various mRNA, most of which were significant (P<0.05). The combination of imidapril and fasudil further improved fibrotic area (-52%), DHE-positive area (-26%), alpha-SMA-positive area (-33%), F4/80-positive area (-62%) and the expression of various mRNA (all P<0.05 vs. monotherapy). Compared with either agent alone, the combination of an ACE inhibitor and a Rho-kinase inhibitor was more effective for the prevention of renal interstitial fibrosis because of the inhibition of transforming growth factor-beta/collagen, monocyte/macrophage infiltration, myofibroblast differentiation, inflammation and the oxidative stress pathway.
我们和其他人最近报道了长期 Rho-激酶抑制具有肾保护作用。本研究旨在比较血管紧张素转换酶(ACE)抑制剂(依那普利)、Rho-激酶抑制剂(法舒地尔)和两者联合应用对单侧输尿管梗阻(UUO)诱导的肾间质纤维化的影响。我们还试图阐明其中涉及的机制。依那普利(50mg/L)、法舒地尔(1g/L)或两者联合应用于饮用水中,比较它们对 UUO 诱导的肾间质纤维化的影响。通过 UUO 评估肾脏组织学发现、单核/巨噬细胞浸润、肌成纤维细胞分化、氧化应激和各种 mRNA 的表达。UUO 后 11 天,野生型肾脏的特征是纤维化面积增加、二氢乙啶(DHE)阳性面积增加、α-平滑肌肌动蛋白(α-SMA)阳性面积增加、F4/80 阳性面积增加和各种 mRNA 的表达增加。法舒地尔和依那普利同样改善了纤维化面积(-23%,-15%)、DHE 阳性面积(-13%,-11%)、α-SMA 阳性面积(-22%,-15%)、F4/80 阳性面积(-42%,-34%)和各种 mRNA 的表达,其中大多数具有统计学意义(P<0.05)。依那普利和法舒地尔联合应用进一步改善了纤维化面积(-52%)、DHE 阳性面积(-26%)、α-SMA 阳性面积(-33%)、F4/80 阳性面积(-62%)和各种 mRNA 的表达(与单药治疗相比均为 P<0.05)。与单独使用任一药物相比,ACE 抑制剂和 Rho-激酶抑制剂联合应用更能有效预防肾间质纤维化,因为它抑制了转化生长因子-β/胶原、单核/巨噬细胞浸润、肌成纤维细胞分化、炎症和氧化应激途径。